Literature DB >> 22270332

Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.

Shuichi Iwahashi1, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka.   

Abstract

PURPOSE: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are important enzymes in the metabolism of 5-fluorouracil, which have been examined as possible predictive markers. We conducted this study to clarify the role of TS and DPD expressions in gallbladder carcinoma (GBC).
METHODS: The subjects were 28 patients who underwent surgical resection of GBC. We examined intratumoral TS and DPD mRNA expressions, using the Danenberg tumor profile method. The expression levels were classified into two groups, based on median values. Clinicopathological variables, including prognosis, were then compared between the high and low expression groups.
RESULTS: There was a significant difference in the incidence of lymph node metastasis between the high and low TS expression groups. The incidence of advanced clinical stage was higher in the low TS expression group than in the high TS expression group. However, no clear correlation was observed between the DPD mRNA expression and any clinicopathological variable. There was no significant difference in the postoperative survival rates between the groups, in accordance with the expression of TS or DPD genes.
CONCLUSION: Low TS mRNA was correlated with a high incidence of lymph node metastasis and advanced clinical stage. Therefore, TS gene expression may help identify patients at increased risk of the progression of GBC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270332     DOI: 10.1007/s00595-012-0118-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  26 in total

1.  Should the extrahepatic bile duct be resected or preserved in R0 radical surgery for advanced gallbladder carcinoma? Results of a Japanese Society of Biliary Surgery Survey: a multicenter study.

Authors:  Tatsuo Araida; Ryouta Higuchi; Mie Hamano; Yoshihito Kodera; Nobuhiro Takeshita; Takehiro Ota; Tatsuya Yoshikawa; Masakazu Yamamoto; Ken Takasaki
Journal:  Surg Today       Date:  2009-09-24       Impact factor: 2.549

2.  The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.

Authors:  Stefano Cereda; Paolo Passoni; Michele Reni; Maria G Viganò; Luca Aldrighetti; Roberto Nicoletti; Eugenio Villa
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

3.  Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.

Authors:  Seiji Obara; Kazumi Yamamoto; Nao Hosogai; Yasuro Yoshimura
Journal:  Oral Oncol       Date:  2005-03       Impact factor: 5.337

4.  Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma.

Authors:  Akira Nii; Mitsuo Shimada; Toru Ikegami; Yukari Harino; Satoru Imura; Yuji Morine; Hirofumi Kanemura; Yusuke Arakawa; Koji Sugimoto
Journal:  Hepatol Res       Date:  2008-11-25       Impact factor: 4.288

5.  Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.

Authors:  Ryuta Fujii; Akiyoshi Seshimo; Shingo Kameoka
Journal:  Int J Clin Oncol       Date:  2003-04       Impact factor: 3.402

6.  Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.

Authors:  Hiroyuki Baba; Kenichi Teramoto; Toru Kawamura; Akira Mori; Masayuki Imamura; Shigeki Arii
Journal:  Cancer Chemother Pharmacol       Date:  2003-09-11       Impact factor: 3.333

7.  Purification and characterization of dihydropyrimidine dehydrogenase from human liver.

Authors:  Z H Lu; R Zhang; R B Diasio
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

8.  Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.

Authors:  Jason T Lewis; Jayant A Talwalkar; Charles B Rosen; Thomas C Smyrk; Susan C Abraham
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

9.  Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.

Authors:  Yousuke Fukui; Toshinori Oka; Sekio Nagayama; Peter V Danenberg; Kathleen D Danenberg; Masakazu Fukushima
Journal:  Int J Mol Med       Date:  2008-12       Impact factor: 4.101

10.  Molecular predictors of lymph node metastasis in colon cancer: increased risk with decreased thymidylate synthase expression.

Authors:  Avo Artinyan; Rahila Essani; Jeffrey Lake; Andreas M Kaiser; Peter Vukasin; Peter Danenberg; Kathleen Danenberg; Robert Haile; Robert W Beart
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

View more
  3 in total

1.  Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients.

Authors:  Wenhui Sun; Chungen Yan; Shaochang Jia; Jianhua Hu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.

Authors:  Aarti Sharma; Kiran Lata Sharma; Annapurna Gupta; Alka Yadav; Ashok Kumar
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

3.  Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.

Authors:  Rong Xu; Xiaolei He; Reyina Wufuli; Ying Su; Lili Ma; Ru Chen; Zhongcheng Han; Fang Wang; Jiang Liu
Journal:  J Gastric Cancer       Date:  2019-11-13       Impact factor: 3.720

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.